SMSPHARMA — SMS Pharmaceuticals Balance Sheet
0.000.00%
- IN₹27.44bn
- IN₹30.04bn
- IN₹7.83bn
- 64
- 15
- 82
- 56
Annual balance sheet for SMS Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 404 | 466 | 73.8 | 360 | 414 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,262 | 716 | 1,715 | 2,502 | 2,191 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3,093 | 3,771 | 4,106 | 5,339 | 5,545 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4,625 | 4,476 | 4,437 | 4,649 | 5,655 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 8,122 | 8,595 | 8,796 | 10,341 | 11,527 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,941 | 1,965 | 2,549 | 3,317 | 3,244 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 4,017 | 3,892 | 4,191 | 4,978 | 5,130 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 4,105 | 4,703 | 4,605 | 5,363 | 6,396 |
| Total Liabilities & Shareholders' Equity | 8,122 | 8,595 | 8,796 | 10,341 | 11,527 |
| Total Common Shares Outstanding |